Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MDxHealth SA ADR (MDXH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/14/2025: MDXH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.04
1 Year Target Price $7.04
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.68% | Avg. Invested days 37 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 196.50M USD | Price to earnings Ratio - | 1Y Target Price 7.04 |
Price to earnings Ratio - | 1Y Target Price 7.04 | ||
Volume (30-day avg) 6 | Beta -560509.06 | 52 Weeks Range 1.35 - 5.33 | Updated Date 11/16/2025 |
52 Weeks Range 1.35 - 5.33 | Updated Date 11/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-12 | When After Market | Estimate -0.17 | Actual -0.16 |
Profitability
Profit Margin -30.5% | Operating Margin (TTM) -9.63% |
Management Effectiveness
Return on Assets (TTM) -5.52% | Return on Equity (TTM) -720.01% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 236061295 | Price to Sales(TTM) 1.91 |
Enterprise Value 236061295 | Price to Sales(TTM) 1.91 | ||
Enterprise Value to Revenue 2.29 | Enterprise Value to EBITDA -2.73 | Shares Outstanding 49497334 | Shares Floating 35418718 |
Shares Outstanding 49497334 | Shares Floating 35418718 | ||
Percent Insiders 13.22 | Percent Institutions 46.22 |
Upturn AI SWOT
MDxHealth SA ADR
Company Overview
History and Background
MDxHealth SA ADR, originating from Belgium, focuses on developing and commercializing molecular diagnostic tests for personalized cancer treatment. Founded in 2003, it achieved significant milestones with its ConfirmMDx and SelectMDx tests, becoming a leader in prostate cancer diagnostics.
Core Business Areas
- Prostate Cancer Diagnostics: Development and commercialization of tests like SelectMDx and ConfirmMDx to aid in prostate cancer detection and management.
Leadership and Structure
The company has a leadership team comprising a CEO, CFO, and other executives. The organizational structure includes departments for research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- SelectMDx: A urine-based molecular diagnostic test for prostate cancer risk assessment. It reduces unnecessary biopsies by identifying men who can avoid immediate biopsy. Limited market share data is available, but the urology space competition is fierce. Competitors include Exact Sciences(EXAS) with Oncotype DX Genomic Prostate Score and Myriad Genetics (MYGN) with Prolaris.
- ConfirmMDx: A tissue-based epigenetic test used to assess whether a negative prostate biopsy truly rules out cancer. Limited market share data available. Competitors are similar to SelectMDx.
Market Dynamics
Industry Overview
The molecular diagnostics market is growing, driven by the increasing prevalence of cancer and the demand for personalized medicine. It is a rapidly evolving landscape.
Positioning
MDxHealth SA ADR holds a niche position in prostate cancer diagnostics, offering innovative tests to improve patient outcomes and reduce healthcare costs.
Total Addressable Market (TAM)
The TAM for prostate cancer diagnostics is estimated to be billions of dollars globally. MDxHealth SA ADR is positioned to capture a portion of this market with its novel technologies.
Upturn SWOT Analysis
Strengths
- Proprietary molecular diagnostic technologies
- Established presence in prostate cancer testing
- Strong clinical evidence supporting test performance
Weaknesses
- Limited product portfolio
- Reliance on reimbursement policies
- Need for broader market penetration
Opportunities
- Expansion into other cancer types
- Strategic partnerships with healthcare providers
- Increased adoption of molecular diagnostics
Threats
- Competition from established diagnostic companies
- Changes in reimbursement policies
- Emergence of new technologies
Competitors and Market Share
Key Competitors
- EXAS
- MYGN
Competitive Landscape
MDxHealth SA ADR competes with larger, more established diagnostic companies. Its advantages lie in its niche focus and innovative technologies, while its disadvantages include limited resources and market reach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the adoption of SelectMDx and ConfirmMDx tests.
Future Projections: Analyst estimates suggest continued growth driven by increased market penetration and potential expansion into other cancer areas.
Recent Initiatives: Recent strategic initiatives include expanding sales and marketing efforts and pursuing new collaborations.
Summary
MDxHealth SA ADR, while innovative in prostate cancer diagnostics, faces challenges due to its small size and competition. Its SelectMDx and ConfirmMDx tests offer value but require broader adoption. Key opportunities exist in expanding its product portfolio and market reach. The company should carefully manage competition and reimbursement risks.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MDxHealth SA ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-04 | CEO & Executive Director Mr. Michael K. McGarrity | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 312 | Website https://mdxhealth.com |
Full time employees 312 | Website https://mdxhealth.com | ||
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It also offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.